Differential role of monocyte subsets in atherosclerosis

Summary

Endothelial dysfunction and inflammation of the arterial wall continuously drive the development of atherosclerosis. Details regarding the sequential involvement of different monocyte subsets in the pathology of this disease have recently emerged. This review concentrates on major monocyte subpopulations in mouse and men and specifically addresses their phenotype, function and recruitment during primary atherosclerosis as well as their contribution to angiogenesis and tissue regeneration secondary to plaque rupture.

Keywords

Atherosclerosis - chemokines - monocytes

• References

• 1 Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009; 27: 669-692.
• 2 Zhao Y, Glesne D, Huberman E. A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc Natl Acad Sci USA 2003; 100: 2426-2431.
• 3 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
• 4 Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8: 1257-1262.
• 5 Potteaux S, Gautier EL, Hutchison SB. et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest 2011; 121: 2025-2036.
• 6 Llodrá J, Angeli V, Liu J. et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004; 101: 11779-11784.
• 7 Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82.
• 8 Gautier EL, Jakubzick C, Randolph GJ. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 1412-1418.
• 9 Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010; 7: 77-86.
• 10 Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8: 802-815.
• 11 Auffray C, Fogg D, Garfa M. et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007; 317: 666-670.
• 12 Landsman L, Bar-On L, Zernecke A. et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009; 113: 963-972.
• 13 Swirski FK, Libby P, Aikawa E. et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
• 14 Combadière C, Potteaux S, Rodero M. et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008; 117: 1649-1657.
• 15 Tacke F, Alvarez D, Kaplan TJ. et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-194.
• 16 Saederup N, Chan L, Lira SA. et al. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 2008; 117: 1642-1648.
• 17 Boring L, Gosling J, Cleary M. et al. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897.
• 18 Braunersreuther V, Zernecke A, Arnaud C. et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007; 27: 373-379.
• 19 Veillard NR, Kwak B, Pelli G. et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94: 253-261.
• 20 Nahrendorf M, Swirski FK, Aikawa E. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204: 3037-3047.
• 21 Palframan RT, Jung S, Cheng G. et al. Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med 2001; 194: 1361-1373.
• 22 An G, Wang H, Tang R. et al. P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation 2008; 117: 3227-3237.
• 23 Ziegler-Heitbrock L, Ancuta P, Crowe S. et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-80.
• 24 Shantsila E, Lip GY. Monocyte diversity in myocardial infarction. J Am Coll Cardiol 2009; 54: 139-142.
• 25 Ziegler-Heitbrock L. The CD14+CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007; 81: 584-92.
• 26 Weber C, Belge KU, von Hundelshausen P. et al. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol 2000; 67: 699-704.
• 27 Ancuta P, Rao R, Moses A. et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003; 197: 1701-1707.
• 28 Draude G, von Hundelshausen P, Frankenberger M. et al. Distinct scavenger receptor expression and function in the human CD14(+)/CD16(+) monocyte subset. Am J Physiol 1999; 276: H1144-1149.
• 29 Ingersoll MA, Spanbroek R, Lottaz C. et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 2010; 115: e10-19.
• 30 Czepluch FS, Olieslagers S, van Hulten R. et al. VEGF-A-induced chemotaxis of CD16+ monocytes is decreased secondary to lower VEGFR-1 expression. Atherosclerosis 2011; 215: 331-338.
• 31 Shantsila E, Wrigley B, Tapp L. et al. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J Thromb Haemost 2011; 9: 1056-1066.
• 32 Zawada AM, Rogacev KS, Rotter B. et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood. 2011. in press
• 33 Murdoch C, Tazzyman S, Webster S. et al. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007; 178: 7405-7411.
• 34 Urra X, Villamor N, Amaro S. et al. Monocyte subtypes predict clinical course and prognosis in human stroke. J Cereb Blood Flow Metab 2009; 29: 994-1002.
• 35 Mosig S, Rennert K, Krause S. et al. Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+CD16+ monocytes in detoxification of oxidized LDL. FASEB J 2009; 23: 866-874.
• 36 Belge KU, Dayyani F, Horelt A. et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-3542.
• 37 Cros J, Cagnard N, Woollard K. et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33: 375-386.
• 38 Wildgruber M, Lee H, Chudnovskiy A. et al. Monocyte subset dynamics in human atherosclerosis can be profiled with magnetic nano-sensors. PLoS One 2009; 4: e5663
• 39 Madjid M, Awan I, Willerson JT. et al. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004; 44: 1945-1956.
• 40 Rogacev KS, Ulrich C, Blömer L. et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J 2010; 31: 369-376.
• 41 Timmerman KL, Flynn MG, Coen PM. et al. Exercise training-induced lowering of inflammatory (CD14+CD16+) monocytes: a role in the anti-inflammatory influence of exercise?. J Leukoc Biol 2008; 84: 1271-1278.
• 42 Schlitt A, Heine GH, Blankenberg S. et al. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost 2004; 92: 419-424.
• 43 Kashiwagi M, Imanishi T, Tsujioka H. et al. Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis 2010; 212: 171-176.
• 44 Hristov M, Leyendecker T, Schuhmann C. et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-414.
• 45 Rothe G, Gabriel H, Kovacs E. et al. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16: 1437-1447.
• 46 Tsujioka H, Imanishi T, Ikejima H. et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 2009; 54: 130-138.
• 47 Heine GH, Ulrich C, Seibert E. et al. CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 2008; 73: 622-629.
• 48 Rogacev KS, Seiler S, Zawada AM. et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011; 32: 84-92.
• 49 Fernandez Pujol B, Lucibello FC, Gehling UM. et al. Endothelial-like cells derived from human CD14 positive monocytes. Differentiation 2000; 65: 287-300.
• 50 Schmeisser A, Garlichs CD, Zhang H. et al. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res 2001; 49: 671-680.
• 51 Ito WD, Arras M, Winkler B. et al. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 1997; 80: 829-837.
• 52 Fujiyama S, Amano K, Uehira K. et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ Res 2003; 93: 980-989.
• 53 Moldovan NI, Goldschmidt-Clermont PJ, Parker-Thornburg J. et al. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ Res 2000; 87: 378-384.
• 54 Ceradini DJ, Kulkarni AR, Callaghan MJ. et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
• 55 Schubert SY, Benarroch A, Monter-Solans J. et al. Primary monocytes regulate endothelial cell survival through secretion of angiopoietin-1 and activation of endothelial Tie2. Arterioscler Thromb Vasc Biol 2011; 31: 870-875.
• 56 Awad O, Dedkov EI, Jiao C. et al. Differential healing activities of CD34+ and CD14+ endothelial cell progenitors. Arterioscler Thromb Vasc Biol 2006; 26: 758-764.
• 57 Urbich C, Heeschen C, Aicher A. et al. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003; 108: 2511-2516.
• 58 Fadini GP, Miorin M, Facco M. et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45: 1449-1457.
• 59 Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 1584-1595.
• 60 Rehman J, Li J, Orschell CM, March KL. Peripheral blood „endothelial progenitor cells“ are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107: 1164-1169.
• 61 Hristov M, Gümbel D, Lutgens E. et al. Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury. Circulation 2010; 121: 315-324.
• 62 Vasa M, Fichtlscherer S, Adler K. et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885-2890.
• 63 Hristov M, Fach C, Becker C. et al. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis 2007; 192: 413-420.
• 64 Napoli C, Hayashi T, Cacciatore F. et al. Endothelial progenitor cells as therapeutic agents in the microcirculation: an update. Atherosclerosis 2011; 215: 9-22.